Viva Biotech Establishes Boston Branch

• Viva Biotech Holdings Group has officially established a new branch in Boston, USA, marking a critical expansion in its global strategy.

• The Boston branch aims to enhance the company’s CRO-CMC/CDMO services and strengthen its presence in the North American biopharma market.

Viva Biotech Holdings Group has announced the establishment of a new branch in Boston, Massachusetts, as part of its globalisation strategy. The company, renowned for its comprehensive drug research, development, and manufacturing services, will leverage Boston’s robust biopharma ecosystem to deepen its international collaboration networks.

The Boston branch, situated in Cambridge, places Viva Biotech at the heart of a globally recognised hub for life sciences innovation. Surrounded by leading research institutions like Harvard University and MIT, as well as a vibrant community of biotech companies, the location offers strategic opportunities for collaboration and access to cutting-edge advancements. The branch will serve as a key hub within Viva Biotech’s global network, connecting operations in China, the UK, and Europe to deliver seamless services to clients worldwide.

Dr. Cheney Mao, Chairman and CEO of Viva Biotech, emphasised the significance of the new branch, stating, “Boston is a critical hub for global biopharmaceutical innovation… Moving forward, we will further expand our CRO and CDMO business, strengthening early-stage project capabilities to drive future growth.” He highlighted that the expansion aligns with the company’s commitment to enhancing its one-stop drug discovery and manufacturing capabilities.

Dr. Derek Ren, CEO of Viva Biotech (Shanghai), noted that the branch would enable more direct engagement with North American biotech projects. “We can more directly engage with innovative projects in the North American market via Boston Branch, accurately capture the business needs of emerging biotech companies, and further expand our business scale,” he said.